Where most projects stall
New teams assume a contract lab just executes orders. They don’t. Choosing a preclinical CRO without clear technical specifications creates scope drift, repeated assays, and wasted budget. Start by naming the exact readouts you need, the statistical endpoints that matter, and the deliverables you will accept. This prevents late surprises and keeps technical decisions traceable.
Essential questions to force clarity
What assay validation exists and can you see validation data? Who owns raw data and how is it archived? Will the lab provide an analysis-ready dataset or only summary tables? Which SOPs govern critical steps and are they GLP-compliant where required? What tolerance windows trigger repeat runs? Demand short, factual answers. If a provider hedges, they’ll hedge on execution too.
Data and statistics: make standards non-negotiable
Request an a priori analysis plan and a reproducible pipeline. Specify sample-size calculations, primary and secondary endpoints, and the exact statistical tests. Ask for code or scripts used for analysis and a dataset with metadata. When a lab claims “statistical support,” verify the statistician’s background and whether they’ll produce code you can rerun. Re-running should take you less than a day if the deliverables are complete.
Scope, timelines, and change control
Break the project into milestones tied to technical reviews: method qualification, pilot run, full run, final report. Assign clear freeze points where protocol changes stop unless there’s documented justification and cost/time impacts. Define acceptance criteria for each milestone. If you skip this, you’ll pay for iterations and lose weeks while assays get revalidated.
Comparing full-service CROs and specialist labs
Full-service CROs provide integrated workflows: in vivo, bioanalysis, histology, and report synthesis. Specialists offer deeper technical control in one domain. Choose full-service when you want single-point accountability and predictable timelines. Choose specialists when a single assay is mission-critical and requires niche expertise. Ask for case studies that match your exact assay type, not similar-sounding ones.
Experience, evidence and trustworthiness
Verify hands-on experience with projects in your therapeutic area and look for documented audit history. A practical anchor: the Boston–Cambridge biotech cluster routinely publishes outcomes from early-stage preclinical collaborations, and providers working in that ecosystem are often vetted by partners and investors. Check for peer-reviewed methods or conference presentations tied to the lab’s teams. Also confirm regulatory familiarity and inspection readiness by requesting example inspection responses. Finally, demand a written sample chain-of-custody and the lab’s data integrity policy: these are concrete proofs of competence when you choose a preclinical research CRO.
Common mistakes to avoid
Don’t accept vague deliverables. Don’t assume GLP is implied; ask. Don’t outsource decision-making on sample size or endpoints. Don’t ignore intermediate data reviews. Don’t skip a technical kick-off with scientists on both sides. Each mistake costs time and can invalidate months of work.
Wrap-up with a practical stance
Define technical specs, lock acceptance criteria to milestones, demand reproducible analysis, and verify domain experience with published methods or vetted projects. Apply these rules and you reduce risk, shorten timelines, and keep budget reality-aligned—practical outcomes that teams in the field expect from KCI Biotech.